Issue link: http://osercommunicationsgroup.uberflip.com/i/499812
C h a i n D r u g s t o r e D a i l y S u n d a y, A p r i l 2 6 , 2 0 1 5 4 CAMBER GAINS MOMENTUM WITH MULTITUDE OF NEW PRODUCT LAUNCHES With five new launches since the begin- ning of this year alone, Camber is on schedule to add up to 20 new products to its generics portfolio in 2015, including Pantoprazole – the generic for Protonix ® , Rizatriptan – the generic for Maxalt ® , Sildenafil – the generic for Revatio ® , Valsartin – the generic for Diovan ® , and Zolmitriptan – the generic for Zomig ® . According to the 2014 National Prescription Audit by IMS Health, Camber has been recognized as one of the Top 15 pharmaceutical companies in overall dispensed prescriptions and first in growth with an almost 20 per- cent increase in 2014. Camber's com- prehensive line of products includes a wide range of therapeutic categories, including antiretrovirals, antivirals, anticonvulsants, antiulcerants, antieo- platics, cardiovascular drugs, antibac- terials, antidepressants, anti-diabetics and others. Camber is a fully integrated interna- tional phar- m a c e u t i c a l company that m a i n t a i n s quality and integrity in all its products, from API manufacturing to finished dosage. Camber is a wholly owned subsidiary of Hetero Drugs based in Hyderabad, India. Hetero Drugs is a global pharmaceutical, research and development company with an emphasis on API production and man- ufacturing of finished dosage forms. Invagen, an associated company, offers a substantial amount of Camber products that are manufactured in the United States. Collectively, Hetero, Invagen and PHARMACEUTICAL REVERSE LOGISTICS CAN BE DONE COMPLIANTLY AND COST-EFFICIENTLY By Jeff Pepperworth, President, Inmar Healthcare Network. Managing reverse logistics in the phar- maceutical industry can be a nightmare for companies not equipped with the tools, processes and regulatory expertise to navigate what can seem like a mine- field. There are a myriad of challenges, touching every point from physical pro- cessing to financial settlement and dispo- sition management. Too often, in the effort to avoid the risk of heavy fines from regulatory violations, companies choose all-encompassing destruction practices for pharmaceutical product returns. While such practices may result in minimal or no violations, they can also result in missed opportunities to recoup cost through manufacturer credit. Managing the physical processing of outdated, damaged, recalled, withdrawn and discontinued product in the health- care industry is not a sim- ple prospect, and the answer usually doesn't lie in adapting returns processes designed for non-regulated CPG prod- uct in the retail environ- ment. Processing pharma- ceutical product can be costly and time- consuming if not addressed with the appropriate tools and processes. Agility is the key to meeting these challenges, and forward-thinking compa- nies are turning to technology, such as the innovative solutions offered by Inmar, that reduce cost and increase effi- ciency through automated processing, Continued on Page 29 Continued on Page 29 AN INDEPENDENT PUBLICATION NOT AFFILIATED WITH NACDS Lee M. Oser CEO and Editor-in-Chief Jules Denton Kim Forrester Paul Harris Associate Publishers Lorrie Baumann Editorial Director Richard Thompson JoEllen Lowry Jeanie Catron Associate Editors Yasmine Brown Andre Gressieux Graphic Designers Sarah Glenn Caitlyn Roach Customer Service Managers Heather Canale Jamie Green Don Kitch Tara Neal Show Logistics & Distribution Lynn Hilton Account Manager Enrico Cecchi European Sales Chain Drugstore Daily is published by Oser Communications Group ©2015 All rights reserved. Executive and editorial offices at: 1877 N. Kolb Road, Tucson, AZ 85715 520.721.1300/Fax: 520.721.6300 www.osercommunicationsgroup.com European offices located at Lungarno Benvenuto Cellini, 11, 50125 Florence, Italy